REGN - Regeneron Pharmaceuticals, Inc.
401.21 0.00 (0.00%)
After hours: 4:45PM EST
| Previous Close | 404.75 |
| Open | 404.92 |
| Bid | 383.42 x 1400 |
| Ask | 401.22 x 1100 |
| Day's Range | 393.52 - 406.75 |
| 52 Week Range | 281.89 - 421.99 |
| Volume | 818,530 |
| Avg. Volume | 792,935 |
| Market Cap | 43.381B |
| Beta (3Y Monthly) | 1.09 |
| PE Ratio (TTM) | 25.69 |
| EPS (TTM) | 15.62 |
| Earnings Date | Feb 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 429.59 |
- PR Newswire•7 hours ago
Forty of the Nation's Most Brilliant Young Scientists Named Finalists in Regeneron Science Talent Search 2019
Regeneron Pharmaceuticals, Inc. (REGN) and Society for Science & the Public today named 40 finalists in the Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors. The competition, known as the Westinghouse Science Talent Search from 1942-1997 and the Intel Science Talent Search from 1998-2016, is designed to engage and inspire the next generation of scientific leaders. Finalists were selected from a pool of nearly 2,000 highly qualified entrants, all of whom completed an original research project and extensive application process.
- Zacks•8 hours ago
5 Best Biotech Bets Likely to Outperform Estimates in Q4
Let us take a look at five promising biotech stocks for the fourth quarter of 2018.
- Zacks•9 hours ago
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
AbbVie (ABBV) is likely to beat earnings in fourth quarter. Impressive sales of its key drug, Humira and strong growth of Imbruvica and Mavyret are expected to drive fourth-quarter sales.
- Markit•yesterday
See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
# Regeneron Pharmaceuticals Inc ### NASDAQ/NGS:REGN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $175 million over the last one-month into ETFs that hold REGN are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•3 days ago
3 Healthcare Stocks Hitting 52-Week Highs: Are They Buys?
Can the sizzling momentum continue for these high-flying healthcare stocks?
- Investor's Business Daily•5 days ago
These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts
Biotech stocks Gilead Sciences, Biogen and Celgene are set to beat some aspects of Q4 earnings estimates, an analyst predicted, saying he expects conservative guidance.
- PR Newswire•5 days ago
Regeneron to Report Fourth Quarter and Full Year 2018 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2019
TARRYTOWN, N.Y. , Jan. 18, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2018 financial and operating results ...
- Zacks•5 days ago
Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA. The candidate will now enter clinical studies.
- Zacks•6 days ago
J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect
J&J's (JNJ) Pharmaceuticals segment is likely to face difficult comparisons in fourth quarter.
- Markit•6 days ago
See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
# Regeneron Pharmaceuticals Inc ### NASDAQ/NGS:REGN View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $9.52 billion over the last one-month into ETFs that hold REGN are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•6 days ago
Report: Exploring Fundamental Drivers Behind SkyWest, Pacific Biosciences of California, Lennar, Regeneron Pharmaceuticals, MGM Growth Properties, and Cincinnati Bell — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•7 days ago
Regeneron (REGN) Sails Steady on Label Expansion of Drugs
Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.
- Investor's Business Daily•7 days ago
REIT Stocks, Medical Stocks Lead New Buys By The Best Mutual Funds
See how REIT stocks and medical stocks like Amgen, Biogen and Edwards Lifesciences lead the latest list of new buys by the best mutual funds.
- InvestorPlace•8 days ago
3 of the Top Big Pharma Stocks to Buy Now
The JPMorgan (NYSE:JPM) healthcare conference has brought greater awareness to the positive developments ahead for pharmaceutical stocks. Sure enough, the healthcare sector is up 1.3% Tuesday, with pharmaceutical stocks gaining a 1%. And although Big Pharma stocks are up because of the event, aided by a broad market rebound, there are still undervalued stocks in wider healthcare space. * 10 Growth Stocks With the Future Written All Over Them So what are the best stocks in Big Pharma that investors should pick up? The following pharmaceutical companies all have a track record of strong management, high-value product portfolios, and are on pace for continued growth in 2019. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock ### AbbVie (ABBV) AbbVie Inc. (NYSE:ABBV) recapped its many achievements since becoming a public company in 2013. In that time, the company followed through on its mission to create an innovation-driven, patient-focused biotech company. Its revenue growth, which accelerated last year, is proof of its outstanding execution of delivering on new medicines. 2018 Achievements and Outlook: AbbVie expects to deliver on strong growth again this year. Even with biosimilars bringing more competition to its more than $6 billion HUMIRA business, it will ramp up its HCV business in 2018 and will make big investments this year to support new product launches. Imbruvica and Venclexta are two leading mechanisms in the biosimilars that will drive AbbVie's future growth. These investments, or operating costs as seen on the income statement, will pay off as it supports growth over the next decade. Growth Products: AbbVie's hematology and oncology franchise is already annualizing over $4 billion and is growing in the double-digit rates. Upadacitinib and risankizumab, if approved, will come to market later this year and add to revenue. Management affirmed its confidence in the business by authorizing a $5 billion share buyback. Investors interested in ABBV stock should note the upcoming $1.07 dividend. The stock trades ex-dividend on Jan. 14. Source: Shutterstock ### Regeneron Pharmaceuticals (REGN) Regeneron Pharmaceuticals (NASDAQ:REGN) is trending near 52-week highs for good reason. Its atopic dermatitis drug, Dupixent, has a strong prescription growth rate. Patients, despite the costs, are staying with the medication. Eyelea is another source of revenue. And Regeneron is now developing CAR-T therapies. CAR-T Science: Regeneron is effectively disconnecting the CAR-T cell from the CD28 system. In doing so, it will allow its scientists to mix and match them. By having combinatorial specificity, it is possible to get better targeting and higher efficacy for treatments. In the non-small cell lung cancer space, where Keytruda failed, Regeneron hopes its agent is at least as effective as Merck's (NYSE:MRK). * 10 A-Rated Stocks the Smart Money Is Piling Into Core Drivers: Regeneron's core revenue drivers continue to give investors confidence. As mentioned, Dupixent is working out very well for patients. In its last quarter, the drug's global sales were $260 million, or nearly $1 billion annualized. The drug will also treat asthma. Plus, the company has positive data in eosinophilic asthma for reductions in the exacerbations for pulmonary function tests. Given the market size for patients suffering from asthma, Regeneron's revenues are likely to grow at a faster pace than the market expects. Source: Shutterstock ### Amgen (AMGN) Amgen Inc. (NASDAQ:AMGN) highlighted its double-digit earnings per share growth targets at the JPMorgan conference. It will get there by improving its operating margin from 38% to 52%-54%. Saving $1.5 billion will give it the room it needs to raise its return on capital to its shareholders while continuing on its transformation. Growth Drivers: Amgen will launch nine new products in two therapeutic areas. It already increased its global presence from 50 countries (in 2011) to over 100 at the end of last year. Its high R&D investments include those in the genetics space. In particular, deCODE Genetics in Iceland is impressive because it has 1 million people outside of Iceland who are part of the effort. It also ended the year with 500,000 patients in the U.S. who are available to study genotypically and phenotypically. Products: Amgen has six cancer medicines that are in the early stages of product development. Drugs in this space make $4 billion in revenues for Amgen and grew in the double-digit rates in the last twelve months. Looking ahead, Amgen expects to have a strong portfolio of first-in-class molecules. With biospecifics, small molecules, large molecules, its BiTE platform and CAR-Ts, Amgen has the potential to exceed its own growth goals. As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Companies That Could Post Decelerating Profits * 10 A-Rated Stocks the Smart Money Is Piling Into * Mizuho: 7 Long-Term Value Stocks to Buy Now Compare Brokers The post 3 of the Top Big Pharma Stocks to Buy Now appeared first on InvestorPlace.
- Simply Wall St.•8 days ago
Can Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Maintain Its Strong Returns?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
- Investor's Business Daily•8 days ago
How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support
The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.
- GuruFocus.com•8 days ago
5 Companies Hit 52-Week Highs
As of late, multiple companies have managed to achieve yearly highs
- Zacks•8 days ago
Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive?
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Markit•8 days ago
See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
# Regeneron Pharmaceuticals Inc ### NASDAQ/NGS:REGN View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. ETFs that hold REGN had net inflows of $12.71 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Investopedia•12 days ago
3 Biotech Stocks Bubbling Away
Merger and acquisition activity in the healthcare sector has biotech stocks soaring. Explore three stocks feeling the tailwind.
- Insider Monkey•13 days ago
Oakmark Funds’ Bill Nygren Discusses Poor Q4 Performance – He Is Not Losing Confidence
In a recent Q4 2018 commentary, Bill Nygren from Oakmark Funds shared his views on the current fund’s performance and defended its strategy. Mr. Nygren holds the opinion that the companies, in which his fund invested, have performed quite well, but the problem was in the performance of their stocks. It seems that the businesses […]
- InvestorPlace•14 days ago
Market Leadership’s Odd Couple: Wingstop and Regeneron
What do Wingstop (NASDAQ:WING) and Regeneron (NASDAQ:REGN) have in common? Many investors might be inclined to think "not that much." But if you're an investor who is now rightfully bullish on the market, the correct answer is "more than you think." Let me explain. A small-cap restaurant chain dedicated to making sure customers get their fill of delicious wings and one of biotech's larger players -- what could possibly connect Wingstop to Regeneron? The answer is plain and simple -- growth and overall solid fundamentals, as well as very similar and historically supportive price charts in WING stock and shares of REGN. Some might ask further questions: "What about China, the Federal Reserve, a looming recession and late December's official welcoming of the broader averages into a bear market?" My answer is, go ahead and worry. But if you want to make smart investments after a strong correction, a welcoming over-the-top spike in market volatility to historically extreme levels and last Friday's strong, time-tested "follow-through day" rebuttal; it's time to put WING and REGN stock on the radar. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### Pairs Stock Strategy Long: WING Stock Wingstop is a relative newcomer to the market. Shares of WING IPO'ed back in mid-2015, but don't let youth as a publicly traded company stop you from buying the restaurant operator. Bottom line, this relative newbie to the market has been growing solidly. * 10 Stocks You Can Set and Forget (Even In This Market) Another support is the fact that stocks like WING most often make their biggest gains while they're younger and the law of large numbers isn't yet such a burden. As such, there's little reason to think WING stock can't become a good deal bigger from today's current $2 billion capitalization as the company spreads its wings (no pun intended). On the price chart of WING stock, shares look equally tasty. A technically constructive "W," or high-level double-bottom corrective base, has formed over the last few months on the heels of a solid uptrend to all-time highs over the course of a year or so. As corrections happen to even the most favored stocks, the recent price action in Wingstop of late could be labeled as being inevitable and not something to be feared. Even better, as the technical pause has consolidated gains in a healthy manner during the broader market's less-seemly correction; the W base in WING stock also represents solid-looking leadership as the averages attempt to re-establish a bull market. For bullish investors interested in nibbling on WING stock, shares are in position today to be purchased as they've already cleared the pattern's mid-pivot of $66.41 from early December. Waiting for a breakout to fresh all-time-highs is an option too. Either way, using an 8% stop-loss looks about right as to ensure Wingstop investors don't get fried. ### Pairs Stock Strategy Long No. 2: REGN Stock Regarding the big picture of the last few years, its true shares of Regeneron look a bit different than WING stock on the price chart. It's more than a bit obvious REGN isn't sporting anything remotely like Wingstop's sturdy-looking uptrend of the past couple years. However, both names do share the same bullish W, or double-bottom basing pattern. In this instance, Regeneron's chart formation has developed as a corrective variation following a small uptrend off REGN's move to four-year lows. It's our contention that the combination, along with REGN's strong fundamentals, are setting the stage for an emerging and powerful bullish trend in 2019 for this biotech giant. I'll be frank -- REGN stock can be treacherous. Despite its size and market reach, Regeneron has shown a knack for being volatile. Sometimes this quality is supportive for investors. But it can be equally challenging due to price gaps, as well as sharp and fast moves in shares. For investors still interested in going long Regeneron, like Wingstop, shares are in position to be purchased just pennies above the early December pattern mid-point of $396.32. I'd use still use an 8% stop here, as it amounts to a four-day low and would all but negate the breakout of the base's mid-pivot entry. Alternatively and for more risk-averse bulls, buying the May $420/$440 bull call spread looks like a way to enjoy strong profits if a new leg up begins while minimizing and containing exposure in REGN stock to a known amount of risk. Investment accounts under Christopher Tyler's management do not currently own positions in any securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional options-based strategies, related musings or to ask a question, you can find and follow Chris on Twitter @Options_CAT and StockTwits. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks to Buy for Winning the Online Battle * The 7 Best Stocks in the Entrepreneur Index * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post Market Leadershipas Odd Couple: Wingstop and Regeneron appeared first on InvestorPlace.
- Zacks•14 days ago
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
- Markit•14 days ago
See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
# Regeneron Pharmaceuticals Inc ### NASDAQ/NGS:REGN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding REGN are favorable, with net inflows of $14.65 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•15 days ago
4 Biotechs That Are Potential Buyouts Post Celgene Deal
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.
